4th Quarter - Report

THE D MAJOR GROUP for EMD SERONO, INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

Work on pharmaceutical reporting matters related to H.R. 133, the "Consolidated Appropriations Act of 2021."

LobbyistCovered position, as disclosed
DIANE MAJOR Health Policy Analyst for Senate Republican Policy Committee
BRENDA REESE Conference Coordinator for House Republican Conference

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 133 (116th)

Medicare/Medicaid MMM

Monitor Medicare Part B & D policy changes related to S. 2543, the Prescription Drug Pricing Reduction Act; HR 3, Lower Drug Costs Now Act; and S. 3129 and HR 19, the Lower Costs, More Cures Act.

LobbyistCovered position, as disclosed
DIANE MAJOR Health Policy Analyst for Senate Republican Policy Committee
BRENDA REESE Conference Coordinator for House Republican Conference

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 19 (116th), H.R. 3 (116th), S. 2543 (116th), S. 3129 (116th)

Copyright/Patent/Trademark CPT

Monitor pharmaceutical R&D investment issues related patent protection.

LobbyistCovered position, as disclosed
DIANE MAJOR Health Policy Analyst for Senate Republican Policy Committee
BRENDA REESE Conference Coordinator for House Republican Conference

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.